IPO Edge and CorpGov will be conducting interviews from the floor of the New York Stock Exchange on Feb. 3, 2026. We invite guests to join 15-minute fireside chats recorded in a multi camera high-definition television studio at the NYSE. All content...

By Karen Roman Ascentage Pharma Group Internat (Nasdaq: AAPG) said its treatment candidate for B-cell diseases APG-3288 was granted the investigational new drug clearance by the FDA. The company will also conduct a global Phase I study evaluating APG-3288 in...

By Karen Roman Vinson & Elkins said Vinay Prabhakar is its new partner at the firm’s tax practice in New York, having previously served as Managing Director and Head of Tax at Global Infrastructure Partners (GIP), now part of BlackRock,...

By Exec Edge Editorial Staff Behind every scientific breakthrough at Colossal Biosciences stands a question that transcends technology: Should we? While genetic engineering capabilities have advanced dramatically, the ethical frameworks ensuring responsible use remain paramount. For Colossal’s de-extinction work—including the...

By Exec Edge Editorial Staff John McEntee, the former University of Connecticut quarterback who went on to become a key political figure in U.S. Conservative politics under President Donald Trump, has made a substantial financial contribution to UConn’s football program,...

By Karen Roman Biopharmaceutical company Medera Inc. said it completed patient enrollment for Cohort B of its clinical trial evaluating SRD-002 gene therapy for heart failure with preserved ejection fraction (HFpEF). This milestone allows Medera to advance to Phase 2b...

The Dubai royal’s investment approach through Inmā Emirates Holdings demonstrates how patient capital and technology transfer can generate measurable social impact across emerging markets By Exec Edge Editorial Staff The language of impact investing has evolved from philanthropic experiment to...

By Karen Roman SkylineDx said it published new peer-reviewed data where its Merlin CP-GEP Test outperforms the competition and current standards of care for identifying melanoma risk using molecular testing. In response to a competitor’s study comparing its own test...

Download the Complete Report Here By Brandon Hornback Seeking a stock-market bargain to brighten the holidays? Savvy investors should consider a single equity that captures the best of the burgeoning Telegram ecosystem, cryptocurrency at a discount and top-notch AI assets,...

Subscribe to our Weekly Newsletter to Receive All Research Contact: Executives-Edge.com Rayk@capmarketsmedia.com